EGFR and lung adenocarcinoma: To dramatically change the outlook for patients with lung adenocarcinoma, it is essential to identify target that may be exploitable in relapsed EGFR‐mutant tumors as well as in lung adenocarcinomas lacking mutations in druggable targets.